Felix K. Yam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Felix K. Yam has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Satish A. Eraly
VA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA, USA; UC San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
2 shared publications- Aimee G. Adams
College of Pharmacy, University of Kentucky . Lexington, KY ( United States ). argelh1@.uky.edu
1 shared publication - Brian Kwan
Department of Medicine, University of California, San Diego, San Diego, California; Jennifer Moreno Department of Veterans Affairs Medical Center, San Diego, California
1 shared publication - Candis M. Morello
San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, CA 92093, USA
1 shared publication - Charles Edward Daniels
San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, CA 92093, USA
1 shared publication - Christina Louise Mnatzaganian
University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, and University of California San Diego Health , La Jolla, CA
1 shared publication
Latest Publications
- 9 May 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (5) , 947-958
Evolution of clinical pharmacy practice and pharmacy education in Taiwan, Vietnam, and Indonesia: A narrative review
In this narrative review, we trace the evolution of health care, clinical pharmacy practice, and pharmacy education in Taiwan and two Southeast Asian countries, Vietnam and Indonesia. In evaluating the current health‐care systems and progress toward health‐care reform, we review the major changes that have impacted pharmacy practice and pharmacy education in each of these countries. The lack of qualified and well‐trained pharmacists has been identified as one of the key barriers to advancement of clinical pharmacy in this region. This shortage is based on a number of factors which include having a pharmacy education system that needs reform and expansion to adequately meet the growing demands of global public health. Many initiatives from organizations such as the World Health Organization, the International Pharmaceutical Federation, and the Federation of Asian Pharmaceutical Associations have influenced the advancement of global pharmacy practice and education. Moreover, we highlight key legislative changes that have impacted clinical pharmacy development in these countries and discuss how foreign policy changes in Taiwan have increased its collaboration with foreign pharmacy schools in Vietnam and Indonesia. Understanding the history and progress of clinical pharmacy education in these countries is important to help shape future collaborations that advance pharmacy practice and improve global health.
- 9 May 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (5) , 947-958
Evolution of clinical pharmacy practice and pharmacy education in Taiwan, Vietnam, and Indonesia: A narrative review
In this narrative review, we trace the evolution of health care, clinical pharmacy practice, and pharmacy education in Taiwan and two Southeast Asian countries, Vietnam and Indonesia. In evaluating the current health‐care systems and progress toward health‐care reform, we review the major changes that have impacted pharmacy practice and pharmacy education in each of these countries. The lack of qualified and well‐trained pharmacists has been identified as one of the key barriers to advancement of clinical pharmacy in this region. This shortage is based on a number of factors which include having a pharmacy education system that needs reform and expansion to adequately meet the growing demands of global public health. Many initiatives from organizations such as the World Health Organization, the International Pharmaceutical Federation, and the Federation of Asian Pharmaceutical Associations have influenced the advancement of global pharmacy practice and education. Moreover, we highlight key legislative changes that have impacted clinical pharmacy development in these countries and discuss how foreign policy changes in Taiwan have increased its collaboration with foreign pharmacy schools in Vietnam and Indonesia. Understanding the history and progress of clinical pharmacy education in these countries is important to help shape future collaborations that advance pharmacy practice and improve global health.
- Open Access
Advancing Pharmacist Collaborative Care within Academic Health Systems
Introduction: The scope of pharmacy practice has evolved over the last few decades to focus on the optimization of medication therapy. Despite this positive impact, the lack of reimbursement remains a significant barrier to the implementation of innovative pharmacist practice models. Summary: We describe the successful development, implementation and outcomes of three types of pharmacist collaborative care models: (1) a pharmacist with physician oversight, (2) pharmacist–interprofessional teams and (3) physician–pharmacist teams. The outcome measurement of these pharmacist care models varied from the design phase to patient volume measurement and to comprehensive quality dashboards. All of these practice models have been successfully funded by affiliated health systems or grants. Conclusions: The expansion of pharmacist services delivered by clinical faculty has several benefits to affiliated health systems: (1) significant improvements in patient care quality, (2) access to experts in specialty areas, and (3) the dissemination of outcomes with national and international recognition, increasing the visibility of the health system.
Open AccessAdvancing Pharmacist Collaborative Care within Academic Health Systems
Introduction: The scope of pharmacy practice has evolved over the last few decades to focus on the optimization of medication therapy. Despite this positive impact, the lack of reimbursement remains a significant barrier to the implementation of innovative pharmacist practice models. Summary: We describe the successful development, implementation and outcomes of three types of pharmacist collaborative care models: (1) a pharmacist with physician oversight, (2) pharmacist–interprofessional teams and (3) physician–pharmacist teams. The outcome measurement of these pharmacist care models varied from the design phase to patient volume measurement and to comprehensive quality dashboards. All of these practice models have been successfully funded by affiliated health systems or grants. Conclusions: The expansion of pharmacist services delivered by clinical faculty has several benefits to affiliated health systems: (1) significant improvements in patient care quality, (2) access to experts in specialty areas, and (3) the dissemination of outcomes with national and international recognition, increasing the visibility of the health system.
- 18 May 2017
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 39 (4) , 831-835
Evaluation of the effect of torsemide on warfarin dosage requirements
Background According to drug interaction databases, torsemide may potentiate the effects of warfarin. Evidence for this drug–drug interaction, however, is conflicting and the clinical significance is unknown. Objective The aim of this study is to evaluate the impact of torsemide initiation on warfarin dosage requirements. Setting This study was conducted at the Veterans Affairs Healthcare System in San Diego, California. Method A retrospective cohort study was conducted using Veterans Affairs data from patients who were converted from bumetanide to torsemide between March 2014 and July 2014. Patients were also prescribed and taking warfarin during the observation period. Warfarin dosage requirements were evaluated to determine if any changes occurred within the first 3 months of starting torsemide. Main outcome measure The primary outcome was the average weekly warfarin dose before and after torsemide initiation. Results Eighteen patients met study inclusion criteria. The weekly warfarin dose before and after initiation of torsemide was not significantly different (34 ± 15 and 34 ± 13 mg, p > 0.05). Of those eighteen patients, only two experienced elevations in INR that required a decrease in warfarin dosage after torsemide initiation. Between those two patients, dosage reductions ranged from 5.3 to 18%. Conclusion These results indicated that most patients did not require any warfarin dosage adjustments after torsemide was initiated. The potential for interaction, however, still exists. While empiric warfarin dosage adjustments are not recommended when initiating torsemide, increased monitoring is warranted to minimize the risk of adverse effects
- 18 May 2017
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 39 (4) , 831-835
Evaluation of the effect of torsemide on warfarin dosage requirements
Background According to drug interaction databases, torsemide may potentiate the effects of warfarin. Evidence for this drug–drug interaction, however, is conflicting and the clinical significance is unknown. Objective The aim of this study is to evaluate the impact of torsemide initiation on warfarin dosage requirements. Setting This study was conducted at the Veterans Affairs Healthcare System in San Diego, California. Method A retrospective cohort study was conducted using Veterans Affairs data from patients who were converted from bumetanide to torsemide between March 2014 and July 2014. Patients were also prescribed and taking warfarin during the observation period. Warfarin dosage requirements were evaluated to determine if any changes occurred within the first 3 months of starting torsemide. Main outcome measure The primary outcome was the average weekly warfarin dose before and after torsemide initiation. Results Eighteen patients met study inclusion criteria. The weekly warfarin dose before and after initiation of torsemide was not significantly different (34 ± 15 and 34 ± 13 mg, p > 0.05). Of those eighteen patients, only two experienced elevations in INR that required a decrease in warfarin dosage after torsemide initiation. Between those two patients, dosage reductions ranged from 5.3 to 18%. Conclusion These results indicated that most patients did not require any warfarin dosage adjustments after torsemide was initiated. The potential for interaction, however, still exists. While empiric warfarin dosage adjustments are not recommended when initiating torsemide, increased monitoring is warranted to minimize the risk of adverse effects
- 1 September 2016
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 12 (5) , 713-721
Changes in medication regimen complexity and the risk for 90-day hospital readmission and/or emergency department visits in U.S. Veterans with heart failure
- 1 September 2016
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 12 (5) , 713-721
Changes in medication regimen complexity and the risk for 90-day hospital readmission and/or emergency department visits in U.S. Veterans with heart failure
- 1 September 2014
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 71 (17) , 1457-1461
A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline
A case of profound neutropenia and agranulocytosis associated with the off-label use of ceftaroline is reported. A 67-year-old Caucasian man arrived at the emergency room with right shoulder pain and weakness that radiated to his right chest, back, and right arm. A review of symptoms was notable for two days of burning with urination associated with decreased urinary output and decreased appetite. Multiple tests revealed the presence of methicillin-resistant Staphylococcus aureus (MRSA) septic arthritis, which was treated with an off-label dosage of ceftaroline (600 mg intravenously every eight hours). At the start of ceftaroline therapy, the patient's baseline absolute neutrophil count (ANC) was 6640 cells/μL and decreased to 816 cells/μL by day 19, eventually falling to 0 cells/μL on day 21 of therapy. Ceftaroline was then discontinued due to the suspicion that the neutropenia was secondary to maturation arrest of the bone marrow. The patient was switched to i.v. daptomycin to finish a six-week course of antibiotics. Interventional radiology placed a drain in the patient's right shoulder during the hospital stay, with symptom improvement. His white blood cell count continued to increase after ceftaroline discontinuation, reaching 6.5×10(3) cells/μL with a differential of 56.6% segmented neutrophils and 28.4% lymphocytes after nine days off of ceftaroline. A 67-year-old man developed profound neutropenia and agranulocytosis after three weeks of high-dose ceftaroline therapy for the treatment of MRSA septic arthritis. His neutropenia resolved after ceftaroline discontinuation and treatment with an alternative antibiotic.
- 1 September 2014
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 71 (17) , 1457-1461
A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline
A case of profound neutropenia and agranulocytosis associated with the off-label use of ceftaroline is reported. A 67-year-old Caucasian man arrived at the emergency room with right shoulder pain and weakness that radiated to his right chest, back, and right arm. A review of symptoms was notable for two days of burning with urination associated with decreased urinary output and decreased appetite. Multiple tests revealed the presence of methicillin-resistant Staphylococcus aureus (MRSA) septic arthritis, which was treated with an off-label dosage of ceftaroline (600 mg intravenously every eight hours). At the start of ceftaroline therapy, the patient's baseline absolute neutrophil count (ANC) was 6640 cells/μL and decreased to 816 cells/μL by day 19, eventually falling to 0 cells/μL on day 21 of therapy. Ceftaroline was then discontinued due to the suspicion that the neutropenia was secondary to maturation arrest of the bone marrow. The patient was switched to i.v. daptomycin to finish a six-week course of antibiotics. Interventional radiology placed a drain in the patient's right shoulder during the hospital stay, with symptom improvement. His white blood cell count continued to increase after ceftaroline discontinuation, reaching 6.5×10(3) cells/μL with a differential of 56.6% segmented neutrophils and 28.4% lymphocytes after nine days off of ceftaroline. A 67-year-old man developed profound neutropenia and agranulocytosis after three weeks of high-dose ceftaroline therapy for the treatment of MRSA septic arthritis. His neutropenia resolved after ceftaroline discontinuation and treatment with an alternative antibiotic.
- Open Access
- 1 December 2013
- Published by SciELO Espana/Repisalud in Pharmacy Practice
- Vol. 11 (4) , 203-210
Clinical inertia in type 2 diabetes: a retrospective analysis of pharmacist-managed diabetes care vs. usual medical care
Evidence suggests that patients with type 2 diabetes (T2DM) suffer from a high rate of "clinical inertia" or "recognition of the problem but failure to act." THE AIM OF THIS STUDY IS TO QUANTIFY THE RATE OF CLINICAL INERTIA BETWEEN TWO MODELS OF CARE: Pharmacist-Managed Diabetes Clinic (PMDC) vs. Usual Medical Care (UMC). Patients in a university based medical clinic with type 2 diabetes (T2DM) were analyzed in this retrospective cohort study. Patients were exposed to either PMDC or UMC. The difference in days to intervention in response to suboptimal laboratory values and time to achieve goal hemoglobin A1c (A1c), systolic blood pressure (SBP) and low-density lipoprotein (LDL) was compared in the two models of care. A total of 113 patients were included in the analysis of this study, 54 patients were in the PMDC and 59 patients were in the UMC group. Median time (days) to intervention for A1c values >7% was 8 days and 9 days in the PMDC and UMC groups, respectively (p>0.05). In patients with baseline A1c values >8%, median time to achieving A1c<7% was 259 days vs. 403 days in the PMDC and UMC groups, respectively (p<0.05). Median time to goal SBP was 124 days in the PMDC group and 532 days in the UMC group (p<0.05). Median time to goal LDL was 412 days in the PMDC group vs. 506 days in the UMC group (p<0.05). Rates of clinical inertia, defined as time to intervention of suboptimal clinical values, did not differ significantly between patients enrolled in a PMDC compared to patients with UMC with respect to A1c, SBP and LDL. Participation in PMDC, however, was associated with achieving goal A1c, SBP, and LDL levels sooner compared to UMC.
- 1 December 2013
- Published by SciELO Espana/Repisalud in Pharmacy Practice
- Vol. 11 (4) , 203-210
Open AccessClinical inertia in type 2 diabetes: a retrospective analysis of pharmacist-managed diabetes care vs. usual medical care
Evidence suggests that patients with type 2 diabetes (T2DM) suffer from a high rate of "clinical inertia" or "recognition of the problem but failure to act." THE AIM OF THIS STUDY IS TO QUANTIFY THE RATE OF CLINICAL INERTIA BETWEEN TWO MODELS OF CARE: Pharmacist-Managed Diabetes Clinic (PMDC) vs. Usual Medical Care (UMC). Patients in a university based medical clinic with type 2 diabetes (T2DM) were analyzed in this retrospective cohort study. Patients were exposed to either PMDC or UMC. The difference in days to intervention in response to suboptimal laboratory values and time to achieve goal hemoglobin A1c (A1c), systolic blood pressure (SBP) and low-density lipoprotein (LDL) was compared in the two models of care. A total of 113 patients were included in the analysis of this study, 54 patients were in the PMDC and 59 patients were in the UMC group. Median time (days) to intervention for A1c values >7% was 8 days and 9 days in the PMDC and UMC groups, respectively (p>0.05). In patients with baseline A1c values >8%, median time to achieving A1c<7% was 259 days vs. 403 days in the PMDC and UMC groups, respectively (p<0.05). Median time to goal SBP was 124 days in the PMDC group and 532 days in the UMC group (p<0.05). Median time to goal LDL was 412 days in the PMDC group vs. 506 days in the UMC group (p<0.05). Rates of clinical inertia, defined as time to intervention of suboptimal clinical values, did not differ significantly between patients enrolled in a PMDC compared to patients with UMC with respect to A1c, SBP and LDL. Participation in PMDC, however, was associated with achieving goal A1c, SBP, and LDL levels sooner compared to UMC.
- 1 February 2012
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 69 (3) , 217-220
Syndrome of inappropriate antidiuretic hormone associated with moxifloxacin
Purpose A possible case of moxifloxacin-induced syndrome of inappropriate antidiuretic hormone (SIADH) is reported. Summary A 66-year-old Caucasian woman with stage II chronic obstructive pulmonary disease (COPD) arrived at the emergency department from an outpatient clinic complaining of worsening shortness of breath, headache, body aches, and dizziness. Five days before her arrival at the hospital, the patient was seen in an outpatient clinic with symptoms of COPD exacerbation and was given a corticosteroid taper of prednisone 40 mg daily and moxifloxacin 400 mg daily. The patient was hospitalized, and her serum sodium concentration was 110 meq/L. Moxifloxacin was continued on admission, and the patient was admitted to the intensive care unit for frequent neurologic examination, serial serum sodium measurements, and fluid restriction. Her laboratory test results were consistent with SIADH. Fluid restriction at 1 L/day initially corrected her serum sodium concentration to 119 meq/L, but increases in serum sodium plateaued by day 2 of admission (119–122 meq/L). Moxifloxacin was discontinued on hospital day 3. At discharge, on hospital day 5, her serum sodium concentration had increased to 131 meq/L. She was restarted on her home medications and followed up in an outpatient clinic one week later. After multiple etiologies were ruled out, drug-induced SIADH associated with moxifloxacin was the most likely diagnosis for this patient. Clinicians should be aware of this potential adverse drug effect when assessing patients with hyponatremia or SIADH. Conclusion A 66-year-old woman developed severe hyponatremia after receiving moxifloxacin for five days for treatment of COPD exacerbation.
- 1 February 2012
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 69 (3) , 217-220
Syndrome of inappropriate antidiuretic hormone associated with moxifloxacin
Purpose A possible case of moxifloxacin-induced syndrome of inappropriate antidiuretic hormone (SIADH) is reported. Summary A 66-year-old Caucasian woman with stage II chronic obstructive pulmonary disease (COPD) arrived at the emergency department from an outpatient clinic complaining of worsening shortness of breath, headache, body aches, and dizziness. Five days before her arrival at the hospital, the patient was seen in an outpatient clinic with symptoms of COPD exacerbation and was given a corticosteroid taper of prednisone 40 mg daily and moxifloxacin 400 mg daily. The patient was hospitalized, and her serum sodium concentration was 110 meq/L. Moxifloxacin was continued on admission, and the patient was admitted to the intensive care unit for frequent neurologic examination, serial serum sodium measurements, and fluid restriction. Her laboratory test results were consistent with SIADH. Fluid restriction at 1 L/day initially corrected her serum sodium concentration to 119 meq/L, but increases in serum sodium plateaued by day 2 of admission (119–122 meq/L). Moxifloxacin was discontinued on hospital day 3. At discharge, on hospital day 5, her serum sodium concentration had increased to 131 meq/L. She was restarted on her home medications and followed up in an outpatient clinic one week later. After multiple etiologies were ruled out, drug-induced SIADH associated with moxifloxacin was the most likely diagnosis for this patient. Clinicians should be aware of this potential adverse drug effect when assessing patients with hyponatremia or SIADH. Conclusion A 66-year-old woman developed severe hyponatremia after receiving moxifloxacin for five days for treatment of COPD exacerbation.
- 1 March 2005
- Published by SLACK, Inc. in Orthopedics
- Vol. 28 (3) , 275-279
"Collateral Damage": Antibiotics and the Risk of Clostridium Difficile Infection
Antimicrobial selection for orthopedic surgery patients is an important consideration given the increasing incidence and severity of Clostridium difficile infection.
- 1 March 2005
- Published by SLACK, Inc. in Orthopedics
- Vol. 28 (3) , 275-279
"Collateral Damage": Antibiotics and the Risk of Clostridium Difficile Infection
Antimicrobial selection for orthopedic surgery patients is an important consideration given the increasing incidence and severity of Clostridium difficile infection.